Home Newsfeeds Stephens & Co. Maintains Overweight on BellRing Brands, Raises Price Target to $37

Stephens & Co. Maintains Overweight on BellRing Brands, Raises Price Target to $37

Stephens & Co. analyst Ben Bienvenu maintains BellRing Brands (NYSE:BRBR) with a Overweight and raises the price target from $35 to $37.

byBenzinga Newsdesk

February 8, 2023

1 minute read

Stephens & Co. analyst Ben Bienvenu maintains BellRing Brands (NYSE:BRBR) with a Overweight and raises the price target from $35 to $37.

Analyst Ratings

Where Lowe’s Companies Stands With Analysts

By Benzinga Insights

July 12, 1:01 PM

Lowe’s Companies (NYSE:LOW) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

LOW

NanoVibronix Cites Results From Independent Testing Of UroShield

By Happy Mohamed

August 30, 8:34 AM

University of Southampton Study Reports Positive Outcomes in Lab and Patient Testing NanoVibronix, Inc. (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®

NAOV

Inhibikase Therapeutics Initiates Medical And Patient Awareness Campaign For Its Phase 2 ‘201’ Trial Evaluating IkT-148009 In Parkinson’s Disease

By Happy Mohamed

June 21, 8:10 AM

- Company to highlight the '201' trial at multiple regional seminars for physicians - - Up to 61% of clinical sites actively screening patients by close of 2Q23

IKT

Tesla’s Earnings Swoon, Ford Ups Ante With F-150 Lightning Price Cuts, Fisker India-Bound And More: Biggest EV Stories Of The Week

By Shanthi Rexaline

July 22, 8:18 AM

Most underperforming electric vehicle stocks staged a modest comeback in the week that ended on July 21, although…

Stephens & Co. Maintains Overweight on BellRing Brands, Raises Price Target to $37

Related Posts

Where Lowe’s Companies Stands With Analysts

NanoVibronix Cites Results From Independent Testing Of UroShield

Inhibikase Therapeutics Initiates Medical And Patient Awareness Campaign For Its Phase 2 ‘201’ Trial Evaluating IkT-148009 In Parkinson’s Disease

Tesla’s Earnings Swoon, Ford Ups Ante With F-150 Lightning Price Cuts, Fisker India-Bound And More: Biggest EV Stories Of The Week